<DOC>
	<DOCNO>NCT00373594</DOCNO>
	<brief_summary>Chronic cold agglutinin disease ( CAD ) type autoimmune hemolytic anemia ( anemia due destruction red blood cell abnormal antibody ) . Almost patient also suffer cold-induced disturbance blood circulation . The purpose study assess efficacy safety combination therapy rituximab ( antibody B lymphocytes ) fludarabine ( cytotoxic drug ) CAD . Another aim try ass whether agent combination good single agent therapy rituximab .</brief_summary>
	<brief_title>Therapy Chronic Cold Agglutinin Disease</brief_title>
	<detailed_description>1 . Background Chronic cold agglutinin disease ( CAD ) mediate monoclonal cold-reactive autoantibody bind erythrocyte surface antigen , cause haemagglutination complement-mediated haemolysis . Anaemia severe ( Hb 8.0 g/dL low ) one-third patient complement-induced exacerbation febrile illness occur frequently 1-3 . Cold-induced circulatory symptom present 90 % patient may disable 1 . CAD associate overt lymphoma disease traditionally classify primary idiopathic . However , lymphoproliferative bone marrow disorder demonstrate flow cytometry 90 % histology approximately 75 % patient , characterize clonal proliferation CD20+ , κ+ B-cells 1,4,5 . The histological feature lymphoplasmacytic lymphoma 50 % patient 1 . Many standard therapy use autoimmune disease indolent lymphomas inefficient , e.g . corticosteroid , alkylating agent , interferon-α , probably , purine analogue single agent therapy 1,6-8 . Treatment chimeric monoclonal anti-CD20 antibody rituximab show prospective study induce remission half patient 9,10 . Almost response partial , however , median response duration less one year . Further study warrant , therefore , order explore possibility increase response rate duration . The purine analogue , cladribine fludarabine , cyclus dependent , yield partial response rate 30-75 % complete response rate 3-10 % lymphoplasmacytic lymphoma 11,12 . Although probably clinically inefficient monotherapy CAD patient , clinical effect fludarabine report single case 13 , cladribine show induce tumour reduction even condition 8 . In lymphoplasmacytic lymphoma , purine analogue rituximab combination therapy result high response rate prolong remission compare purine analogue single agent therapy 12 . The combination produce favourable result patient related condition cryoglobulinaemia type I 14 . Fludarabine induce autoimmune haemolytic anaemia patient chronic lymphocytic leukaemia , event report CAD patient 13,15 . Moreover , reason assume rituximab therapy reduce risk adverse effect fludarabine 16 . 2 Clinical study The clinical study prospective , non-randomized multicentre study order investigate efficacy safety rituximab fludarabine combination therapy patient CAD . The protocol approve Regional Medical Research Ethics Committee Southern Norway , Norwegian Medicines Agency ( EudraCT nr : 2004-002936-25 ) , Norwegian Social Science Data Services ( Privacy Issue Unit ) . 2.1 Study objectives The major study objective ass efficacy rituximab fludarabine combination patient CAD . The second objective ass safety rituximab fludarabine combination patient CAD . The third objective try ass whether rituximab fludarabine combination superior rituximab monotherapy compare patient received therapy CAD . 2.2 Study design A prospective , non-randomized international multicentre study . Registration Treatment : Day 1 : Rituximab ; 375 mg/m2 Day 1-5 : Fludarabine orally ; 40 mg/m2 Day 28 : Rituximab ; 375 mg/m2 Day 28-33 : Fludarabine orally ; 40 mg/m2 Day 56 : Rituximab ; 375 mg/m2 Day 56-60 : Fludarabine orally ; 40 mg/m2 Day 84 : Rituximab ; 375 mg/m2 Day 84-88 : Fludarabine orally ; 40 mg/m2 Evaluation 2.3 Dose adjustment Doses fludarabine adjust case haematological toxicity renal insufficiency . For detail , see chapter 4.3 . 2.4 Study population 2.4.1 Inclusion criterion 1 . CAD diagnosis define combination - 1 . Chronic haemolysis 2 . Cold agglutinin titre &gt; 64 3 . Positive direct antiglobulin test perform polyspecific antiserum , negative ( weakly positive ) anti-IgG , strongly positive anti-C3d 2 . The presence clonal B-cell lymphoproliferative disorder define - 1 . Monoclonal IgMκ band serum electrophoresis immunofixation , 2 . Lymphocyte phenotype κ/λ-ratio &gt; 3.5 CD20+ , κ+ co-expression , use flowcytometric immunophenotyping bone marrow aspirate 3 . Clinical symptom require treatment , anaemia Raynaud-like symptom 4 . Informed consent 2.4.2 Exclusion criterion 1 . An aggressive lymphoma 2 . Blood lymphocyte count &gt; 50 . 109/L 3 . Non-lymphatic malignant disease basal cell carcinoma 4 . Contra-indications rituximab fludarabine therapy 5 . Inability cooperate 2.5 . Response criteria Responses assess use follow , previously publish definition 8,9,17 : Complete response ( CR ) , Absence anemia , sign hemolysis , clinical symptom CAD , undetectable serum monoclonal protein , sign clonal lymphoproliferation bone marrow histology , immunohistochemistry flow cytometry . Partial response ( PR ) , Stable increase Hb level least 2.0 g/dL normal range , combine reduction serum IgM concentration least 50 % normal range , improvement clinical symptom , transfusion independency . Non-response ( NR ) , Patients meet criterion CR PR . 3 Patient examination inclusion 3.1 History . Clinical radiological examination Year first occurrence clinical symptom register along data haemolytic anaemia , circulatory symptom , cold- fever-induced exacerbation , previous therapy , lymph node enlargement , spleen size ( clinical assessment ) . Chest radiograph abdominal ultrasonography do perform already last four month . 3.2 Blood test Haemolysis detect quantify base Hb , reticulocyte count ( x 109/L ) , LDH , bilirubin haptoglobin . These measurement do twice last two month treatment . The following haematological , biochemical immunological assessment do inclusion : - WBC , leukocyte differential count , platelet count - Iron , transferrin ( TIBC ) , ferritin , cobalamine folate - CRP - Quantification IgM , IgG IgA - Serum electrophoreses immunofixation ( * ) ( Immunofixation must perform even visual assessment agarose electrophoreses show monoclonal band . ) - Cold agglutinin titre ( * ) - Specific direct antiglobulin test ( DAT , direct Coombs ' test ) , i.e . use polyspecific antiserum , anti-C3d anti-IgG ) - Complement assessment ( C3 , C4 CH50 ) ( * , ** ) - CMV VZV antibodies - Freezing 5 ml serum ( * , ** ) - Freezing 5 ml EDTA-blood possible later DNA-based study ( ** ) Remarks : See protocol text . 3.3 Bone marrow examination Centres outside Norway follow guideline list . Norwegian centre refer Norwegian protocol version . I . ) Morphologic assessment bone marrow aspirate perform accord routine participate centre . II . ) A bone marrow trephine biopsy obtain accord routine department . Morphological immunohistochemical assessment do university pathology laboratory experienced haematopathologist . If possible , fresh biopsy specimen prefer . III . ) Flow-cytometric immunophenotyping bone marrow aspirate do university hospital laboratory . Cells wash 37oC order remove cold agglutinin , use previously publish procedure 5 ( Appendix 1 ) equally satisfactory method . The antibody panel comprise CD19 , CD20 , CD5 , kappa , lambda preferably also IgM IgG . The kappa/lambda ratio calculate . CD20 expression register semi-quantitatively 0 , + ++ . IV . ) If possible , 5 ml bone marrow aspirate frozen -70oC purpose later DNA-based examination . 4 Therapy 4.1 Treatment schedule Day 1 : Rituximab ; 375 mg/m2 Day 1-5 : Fludarabine orally ; 40 mg/m2 Day 28 : Rituximab ; 375 mg/m2 Day 28-33 : Fludarabine orally ; 40 mg/m2 Day 56 : Rituximab ; 375 mg/m2 Day 56-60 : Fludarabine orally ; 40 mg/m2 Day 84 : Rituximab ; 375 mg/m2 Day 84-88 : Fludarabine orally ; 40 mg/m2 4.2 Administration precaution Administration monitor rituximab fludarabine therapy accordance manufacturer ' recommendation , official regulation apply participate country , routine procedure participate unit . 4.3 Dose adjustment 4.3.1 Haematological toxicity If ANC &lt; 1,0x109/L and/or platelet &lt; 75x109/L day 1 cycle treatment delay 2 week fludarabine dose reduce 30 mg/m2 remain cycle . Myelosuppression degree subsequent cycle result reduction fludarabine dose 20 mg/m2 . Adjustments rituximab dose do due myelosuppression . 4.3.2 Renal insufficiency In patient creatinine clearance 30-60 ml/min fludarabine dose reduce 20 mg/m2 . Patients creatinine clearance 30 ml/min eligible study . 5 Evaluation 5.1 Follow-up treatment The parameter list must record therapy cycle : Clinical condition , possible adverse effect , need transfusion , Hb , reticulocytes count , WBC include differential count , platelet count , CRP , LDH , ASAT , ALAT , alkaline phosphatase , urea , creatinine , bilirubin haptoglobin . Any adverse effect fludarabine register CRF 2 ( Appendix 3 ) . Any adverse effect rituximab register CRF 3 ( Appendix 4 ) . In case death serious event , report without delay S. Berentsen G. Tjønnfjord well relevant national authority accord regulation apply participate country . 5.2 Follow-up treatment ( first six month ) A . ) The following measurement must do monthly first six month last cycle therapy : I . ) All measurement list Paragraph 5.1 . II . ) Quantification immunoglobulin class . In case reduction previously elevate IgM level normal range , serum electrophoresis immunofixation perform next visit . III . ) Number blood transfusion previous registration . B . ) At first visit cessation therapy , new bone marrow biopsy perform patient histological immunohistochemical sign lymphoproliferative disorder present baseline . If lymphoproliferative bone marrow involvement could detect baseline flow cytometry , flow-cytometric immunophenotyping also repeat visit . C. ) Bone marrow examination also repeat four month last therapy cycle examination three month show sign lymphoma . 5.3 Long-term follow-up When six month pass since cessation treatment , patient follow every third month three year need treatment .</detailed_description>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cold agglutinin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Agglutinins</mesh_term>
	<criteria>1 . CAD diagnosis define combination : Chronic haemolysis Cold agglutinin titre &gt; 64 Positive direct antiglobulin test perform polyspecific antiserum , negative ( weakly positive ) antiIgG , strongly positive antiC3d 2 . The presence clonal Bcell lymphoproliferative disorder define : Monoclonal IgMκ band serum electrophoresis immunofixation , Lymphocyte phenotype κ/λratio &gt; 3.5 CD20+ , κ+ coexpression , use flowcytometric immunophenotyping bone marrow aspirate 3 . Clinical symptom require treatment , anaemia Raynaudlike symptoms 4 . Informed consent 1 . An aggressive lymphoma 2 . Blood lymphocyte count &gt; 50 . 109/L 3 . Nonlymphatic malignant disease basal cell carcinoma 4 . Contraindications rituximab fludarabine therapy 5 . Inability cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Cold agglutinin disease</keyword>
	<keyword>Hemolytic</keyword>
	<keyword>Anemia</keyword>
	<keyword>Lymphoproliferative disease</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Fludarabine</keyword>
</DOC>